Oxazepam

Introduction Overview

Generic Name

Oxazepam

Brand Name

Serax

Dosage Form

oral capsule (10 mg; 15 mg; 30 mg)

Drug Class

Benzodiazepines

Pharmacokinetics

Absorption:
Oxazepam is well absorbed from the gastrointestinal tract after oral administration. Peak plasma concentrations are typically reached within 3 to 4 hours, reflecting its moderate rate of absorption. The drug's bioavailability is high, owing to the absence of significant first-pass metabolism by the liver. Clinical studies indicate that food does not significantly affect the extent of oxazepam absorption, though slight delays in time to peak concentration may occur. The rate of absorption contributes to its slower onset of action compared to some other benzodiazepines.

Distribution:
Oxazepam is moderately lipophilic, allowing it to cross the blood-brain barrier effectively, which is essential for its central nervous system (CNS) effects. It is approximately 90% bound to plasma albumin, which limits the free fraction available for therapeutic action but prolongs its duration in the systemic circulation. The drug has a volume of distribution ranging from 0.2 to 0.4 L/kg, indicating distribution mainly within extracellular fluids. Oxazepam does not accumulate significantly in fatty tissues, making it suitable for elderly patients who have altered body fat composition.

Metabolism:
This drug undergoes hepatic metabolism primarily via glucuronidation by phase II metabolic enzymes, producing inactive oxazepam-glucuronide conjugates. Unlike many benzodiazepines, oxazepam is not metabolized by the cytochrome P450 enzyme system, which lowers the potential for drug-drug interactions involving CYP-mediated pathways. The metabolism is not subject to significant genetic polymorphisms, contributing to predictable pharmacokinetics across diverse populations. Hepatic impairment can reduce clearance, necessitating dose adjustments.

Elimination:
Oxazepam and its inactive metabolites are primarily excreted renally. The elimination half-life ranges from approximately 6 to 24 hours, with an average of 8 to 12 hours, allowing for dosing multiple times daily. Impaired renal function can lead to prolonged elimination and accumulation. The drug does not undergo enterohepatic recirculation. Due to its relatively short half-life compared to some longer-acting benzodiazepines, oxazepam is favored in clinical scenarios requiring intermediate duration of action with limited residual sedation.

Dosage Forms

Available Dosage Forms:
Oxazepam is available exclusively in oral capsule formulations with the strengths of 10 mg, 15 mg, and 30 mg. These capsules facilitate ease of dosing adjustment and adherence.

Dosages for Adults and Adolescents:
For adults, oxazepam is typically administered at doses ranging from 10 to 15 mg taken orally three or four times daily for the management of mild to moderate anxiety disorders. For severe anxiety syndromes or agitation associated with depression, higher doses between 15 to 30 mg orally three or four times daily may be utilized. In the context of alcohol withdrawal, 15 to 30 mg orally three or four times daily is also employed to alleviate withdrawal symptoms such as tremulousness, agitation, and acute inebriation.
Adolescents aged 13 years and older may be treated similarly to adults, with doses initiating at 10 to 15 mg orally three or four times daily for mild to moderate anxiety and escalating up to 30 mg three or four times daily for severe presentations.

Specific Patient Populations:
In geriatric patients, the dosing strategy is cautious due to increased sensitivity and altered pharmacodynamics. Initial dosing generally starts at 10 mg orally three times daily, with incremental increases to 15 mg three or four times daily as tolerated and required. Children under 13 years old generally are not approved for therapy with oxazepam, with insufficient data to ensure safety and efficacy. Caution is advised in patients with hepatic or renal impairment, necessitating dose reduction and careful monitoring.

Dosage Regimen Considerations:
Oxazepam is administered multiple times daily to maintain therapeutic plasma concentrations given its intermediate half-life. Dose titration schedules should consider patient response and adverse event profile, with avoidance of abrupt discontinuation due to risks of withdrawal symptoms. Therapeutic monitoring in certain populations, such as the elderly or those with comorbidities, improves safety.

Mechanism Of Action

Oxazepam belongs to the benzodiazepine class of drugs and exerts its pharmacological effects primarily through positive allosteric modulation of the gamma-aminobutyric acid (GABA) type A receptor complex in the central nervous system. By binding to a specific site on the GABA-A receptor, oxazepam enhances the affinity of GABA, the chief inhibitory neurotransmitter, for its receptor, facilitating increased chloride ion influx into neurons. This hyperpolarizes the neuronal membrane, resulting in decreased excitability and dampening of neuronal firing.

At the molecular level, oxazepam stabilizes the GABA-A receptor in an open state more frequently or for longer durations when GABA is bound, amplifying inhibitory postsynaptic potentials. This potentiation leads to the anxiolytic, sedative, muscle relaxant, and anticonvulsant actions characteristic of benzodiazepines. Importantly, oxazepam does not directly activate GABA-A receptors but requires the presence of GABA to exert its effects, which accounts for its safety profile relative to direct GABA agonists.

Cellular pathways influenced by oxazepam also include modulation of neural circuits involved in anxiety and stress responses, particularly within the amygdala, hippocampus, and limbic system. By enhancing inhibitory neurotransmission within these regions, oxazepam reduces the heightened neuronal activity associated with anxiety and agitation, contributing to symptomatic control.

Clinically, oxazepam's slower onset and intermediate duration of action make it favorable for treating anxiety disorders and managing symptoms of alcohol withdrawal where a gentler pharmacokinetic profile reduces sedation risks and accumulation. Compared to other benzodiazepines such as alprazolam or diazepam, oxazepam's metabolism via glucuronidation and lack of active metabolites limit its toxicity and drug interaction potential, making it suitable for elderly patients and those with liver impairment. Clinical studies support its efficacy in reducing anxiety-related symptoms and improving withdrawal-related agitation with a relatively benign side effect profile when used appropriately.

Pharmacological Actions

Potentiates GABAergic neurotransmission by binding to benzodiazepine sites on GABA-A receptors enhancing neuronal inhibition.
Produces anxiolytic effects by reducing excessive neuronal excitability within limbic system structures.
Exerts sedative and hypnotic action aiding in the relief of agitation and tension.
Provides muscle relaxant effects through central nervous system depression.
Offers anticonvulsant properties by stabilizing neuronal membranes and diminishing seizure activity.
Does not exhibit direct GABA agonism but requires endogenous GABA for effect.
Metabolized via glucuronidation, minimizing cytochrome P450-mediated interactions.
Intermediate half-life reduces accumulation and residual sedation compared to longer-acting benzodiazepines.
Slower onset of action favorable for gradual symptom control.
Useful in managing symptoms of alcohol withdrawal including tremors, agitation, and anxiety.
Minimal active metabolites reduces risk in hepatic impairment.
Indicated for management of mild to severe anxiety syndromes with associated agitation or depression.
Exhibits lower abuse potential relative to certain short-acting benzodiazepines when used as prescribed.
Prolonged withdrawal symptoms possible; necessitates careful dose tapering.
Not recommended for children under 6 years due to lack of sufficient safety data.

Therapeutic Or Clinical Uses

Management of mild-to-moderate anxiety disorders with associated tension, irritability, and agitation.
Treatment of severe anxiety syndromes, including anxiety associated with depression.
Short-term alleviation of symptoms related to acute alcohol withdrawal such as tremulousness, anxiety, and agitation.
Relief of anxiety symptoms in elderly patients with sensitive pharmacodynamics.
Adjunctive therapy for anxiety secondary to organic diseases or functional disorders.
Used to reduce agitation and improve calmness in patients requiring sedation without deep hypnosis.
Management of anxiety-related insomnia when appropriate benzodiazepine use is indicated.
Facilitating withdrawal from alcohol or other substances with CNS hyperexcitability.
Alternative benzodiazepine for patients with hepatic impairment due to favorable metabolism.
Treatment option in patients with contraindications to other benzodiazepines with active metabolites.
Supportive therapy in psychiatric disorders where anxiety is a prominent feature.
Used off-label for situational anxiety where short-term relief is preferred.
May be employed in combination with other psychotropic medications to optimize anxiolytic effect.
Symptomatic treatment in acute stress reactions.
Considered in patients with poor tolerance to short-acting benzodiazepines due to more gradual onset.

Side Or Adverse Effects

Commonly causes drowsiness and sedation, which may impair alertness and cognitive function.
Dizziness or vertigo, leading to increased risk of falls, especially in the elderly.
Headache is reported among users, potentially impacting quality of life.
Potential for respiratory depression especially when combined with opioids or alcohol.
Confusion, disorientation, and memory problems, particularly with prolonged use or overdose.
Unusual mood changes including agitation, irritability, anger, or paranoia.
Ataxia and impaired muscle coordination affecting balance and gait.
Risk of dependence and withdrawal symptoms including tremors and seizures upon abrupt discontinuation.
Hallucinations and severe psychiatric symptoms during withdrawal phases.
Gastrointestinal disturbances including nausea or abdominal discomfort.
Rare hypersensitivity reactions manifested as hives, facial swelling, or breathing difficulties.
Slurred speech or difficulty with fine motor control in toxic doses.
Prolonged drowsiness or sedation in elderly individuals necessitating dose adjustments.
Potential for life-threatening respiratory arrest when misused with CNS depressants.
Long-term use may result in tolerance and diminished therapeutic effect.

Precautions

Use caution in elderly or debilitated patients due to increased sensitivity to sedation and dizziness.
Avoid use in patients with a history of substance abuse or addiction due to dependence risk.
Monitor closely in patients with pre-existing respiratory conditions like COPD or sleep apnea.
Exercise caution during pregnancy; first trimester exposure may harm the fetus and infants may experience withdrawal.
Avoid abrupt discontinuation after long-term therapy to prevent severe withdrawal symptoms.
Adjust dosing in patients with hepatic or renal impairment to reduce accumulation risk.
Ensure careful supervision in patients with depression or suicidal ideation as benzodiazepines may exacerbate symptoms.
Concomitant use with opioids, alcohol, or other CNS depressants increases risk of respiratory depression.
Patients should avoid operating heavy machinery or driving until drug effects are known.
Evaluate for depressive symptoms prior to initiation as oxazepam may mask or worsen depression.
Not recommended for use in children under 6 years due to insufficient safety data.
Use during breastfeeding should be considered carefully as drug transfers into breast milk.
Screen for mental illness and psychosis as oxazepam is contraindicated in psychotic disorders.
Careful dose titration is essential to minimize risks of sedation and cognitive impairment.
Consider alternative therapies in patients with low blood pressure, as oxazepam may exacerbate hypotension.

Warnings

Oxazepam may cause slowed or stopped breathing, particularly if combined with opioids or alcohol.
Misuse or abuse of oxazepam can result in addiction, overdose, or death.
Sudden discontinuation after long-term use can cause life-threatening withdrawal symptoms including seizures.
Emergency medical attention is necessary if symptoms like severe drowsiness, confusion, seizures, or suicidal thoughts occur.
Keep medication out of reach of others to prevent accidental ingestion or abuse.
Avoid alcohol consumption during treatment to prevent enhanced sedation and respiratory depression.
Do not share oxazepam with others, especially those with history of drug addiction.
Extended withdrawal symptoms can persist for up to 12 months or longer post-cessation.
Respiratory depression risk is elevated in patients with underlying respiratory disease or on concurrent CNS depressants.
Use pregnancy category D caution; potential for neonatal withdrawal syndromes exists.
Risk of falls and fractures in elderly due to sedation and impaired balance.
Monitor for paradoxical reactions such as increased anxiety or agitation.
Avoid abrupt cessation; a gradual tapering schedule is recommended to reduce withdrawal risks.
Discontinue therapy promptly if signs of allergic reaction such as hives or swelling develop.
Caregivers should observe for signs of overdose including unresponsiveness and respiratory arrest.

Contraindication

Hypersensitivity to oxazepam or any benzodiazepine component.
Patients with psychosis or history of severe mental illness accompanied by psychotic symptoms.
Severe respiratory insufficiency or compromised pulmonary function.
Acute narrow-angle glaucoma due to potential exacerbation.
Myasthenia gravis owing to muscle relaxant effects increasing muscle weakness.
Sleep apnea syndrome or severe respiratory depression disorders.
Known alcohol or drug intoxication that may potentiate CNS depression.
Severe hepatic insufficiency as metabolism may be impaired.
Concomitant use with other CNS depressants without medical supervision.
History of benzodiazepine sensitivity or paradoxical reactions.
Patients under 6 years of age due to safety and efficacy not established.
Pregnancy during the first trimester unless benefits outweigh potential risks.
Use in breastfeeding mothers without specialist consultation.
Patients with severe hypotension or unstable cardiovascular conditions.
Individuals with a history of benzodiazepine or sedative-hypnotic abuse.

Drug Interactions

Concomitant use with opioid analgesics significantly increases risk of respiratory depression and sedation.
Alcohol use potentiates CNS depressive effects leading to heightened sedation and possible respiratory arrest.
Other CNS depressants including barbiturates, sedative hypnotics, antipsychotics, and muscle relaxants enhance sedative properties.
Concomitant administration with anticonvulsants (e.g., phenytoin) may impact drug efficacy and sedative levels.
Certain antidepressants such as tricyclics or SSRIs may increase CNS depression when combined.
Drugs affecting glucuronidation pathways could theoretically alter oxazepam metabolism, though clinically rare.
Use with antihistamines having sedative properties increases drowsiness and cognitive impairment.
Potential pharmacodynamic interactions with antihypertensives may exacerbate hypotensive effects.
Co-administration with other benzodiazepines can potentiate effects and increase toxicity risk.
Drugs that cause enzyme induction or inhibition generally have minimal impact on oxazepam but merit monitoring.
Concurrent use with herbal supplements like kava or valerian may dangerously increase sedation.
Patients taking CNS stimulants may experience attenuation of oxazepam’s therapeutic effects.
Careful monitoring advised with warfarin or other anticoagulants as benzodiazepines can alter bleeding risk.
Combination with muscle relaxants may lead to additive neuromuscular impairment.
Drug interactions are important to consider for safe dose adjustment and prevention of adverse effects.

Preparations Of The Drug

Oral capsules available in 10 mg strength for mild anxiety and initiation of therapy.
Oral capsules available in 15 mg strength for moderate anxiety and dose titration.
Oral capsules available in 30 mg strength intended for more severe anxiety and agitation symptoms.
Formulated for oral administration ensuring predictable absorption profile.
Packaged in blister packs and bottles with child-resistant caps to enhance safety.
Storage recommended at controlled room temperature away from moisture and heat.
Available as prescription-only medication requiring medical oversight.
Typically dispensed with medication guides outlining risks of dependence and withdrawal.
Supplied without additives that affect hepatic metabolism, enabling safer use in hepatic insufficiency.
No available formulations for parenteral or extended-release dosage forms currently marketed.
Patient counseling includes guidance on adherence to prescribed dose and risk mitigation.
Manufactured according to Good Manufacturing Practices ensuring pharmaceutical quality.
Drug preparations designed for multiple daily dosing schedules due to pharmacokinetic profile.
Varied capsule strengths allow for flexible dosing in special populations including geriatric patients.
Commercially available under brand name Serax and as authorized generics.